Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 32.0; sample size: 40.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 42.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 32.0; sample size: 40.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 42.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 42.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 45.0; human relevance: 85.0; therapeutic relevance: 44.0; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 41.5; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 41.5; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 34.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 79.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 41.5; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 34.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 34.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 78.8; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.3/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 83.8; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.2/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 78.7; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 51.1; sample size: 20.0; recency: 100.0; abstract quality: 65.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.2/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 33.5; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.2/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 26.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 62.2/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 16.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
